We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Thymosin β4 fragment
Lyochem buyer fit
This Lyochem page is intentionally written for research labs, core facilities, and method-development teams qualifying TB-500 as a reference-grade lot. It is not the pharmacy procurement owner for this SKU; the page should win differentiated searches around sequence verification, assay suitability, lot continuity, and data-packet depth.
Overview
TB-500 is a 43-residue synthetic fragment of Thymosin β4, the actin-sequestering protein present in nearly all mammalian cells. Its activity turns on actin binding through the central LKKTETQ motif, which propagates into effects on cell migration, angiogenesis, and tissue regeneration, the foundation for its extensive research record in wound-healing, cardiac-remodeling, and tendon-ligament repair models. Longer than BPC-157, the peptide is serum-stable yet lacks oral bioavailability, confining research protocols to injectable administration. Its tissue-repair literature has drawn US regulatory attention, notably at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting, but that discussion leaves Lyochem's Research-Use-Only scope unchanged. Lyochem supplies TB-500 acetate as a lyophilized reference standard at ≥99.0% HPLC. The 43-mer sits in the upper-middle range for routine SPPS, dependable to make but requiring more purification cycles than shorter sequences like BPC-157, so release leans on peak-integration HPLC plus mass spec to resolve near-coeluting deletion sequences. For a peptide this length, mass alone carries more identity ambiguity than for a 15-mer, which is why LC-MS/MS sequence verification is the qualification test we recommend for any TB-500 lot. Ordering options cover the individual vial and the co-formulated Wolverine Blend pairing it with BPC-157 (standard 5+5 mg per 10 mg vial; custom ratios via Lyochem's custom-synthesis programme).
Applications & buyer fit
Repair peptides — BPC-157, TB-500, B7-33, PEG-MGF — ship primarily to research labs studying tissue-repair, gastrointestinal-mucosa, tendon-ligament, and vascular-endothelial models. The synthesis itself is reliable, but analytical confirmation is where suppliers differ: buyers qualifying a new source should request sequence verification by tandem MS on the first lot and compare against the labelled sequence directly.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
TB-500 has been the subject of US regulatory discussion in compounding-pharmacy contexts; Lyochem supplies it strictly for Research Use Only and does not opine on the destination market's specific eligibility.
Selected literature
Frequently asked questions
Purity is read from the RP-HPLC main-peak area; identity is a separate question. ESI-MS fixes the intact mass but, on a peptide this long, cannot separate two deletion variants of identical residue mass that differ only in position. That gap is closed by LC-MS/MS, whose b- and y-ion ladder reads the actual residue order and demonstrates the LKKTETQ actin-binding motif is present and correctly placed. A complete packet therefore reports HPLC for purity, ESI-MS for mass, and, at supplier qualification, fragment coverage for sequence.
A single co-lyophilized vial mixes two peptides with different masses and different chromatographic retention, so both must resolve on the analytical run. RP-HPLC separates the two peaks and integrates each, ESI-MS confirms both molecular masses independently, and the certificate reports each component against its labelled fill so the stated 5+5 mg ratio is verifiable rather than assumed. Because water and counter-ion apply to the combined solid, the packet should express content net of both, letting a lab reconstitute to defined molar concentrations of each peptide.
Related peptides